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Abstract
Our objective was to compare the pattern of organ dysfunctions and outcomes of critically ill patients with systemic lupus ery-
thematosus (SLE) with patients with other systemic rheumatic diseases (SRD). We studied 116 critically ill SRD patients, 59 
SLE and 57 other-SRD patients. The SLE group was younger and included more women. Respiratory failure (61%) and shock 
(39%) were the most common causes of ICU admission for other-SRD and SLE groups, respectively. ICU length-of-stay was 
similar for the two groups. The 60-day survival adjusted for the groups’ baseline imbalances was not different (P = 0.792). 
Total SOFA scores were equal for the two groups at admission and during ICU stay, although respiratory function was worse 
in the other-SRD group at admission and renal and hematological functions were worse in the SLE group at admission. The 
incidence of severe respiratory dysfunction (respiratory SOFA >2) at admission was higher in the other-SRD group, whereas 
severe hematological dysfunction (hematological SOFA >2) during ICU stay was higher in the SLE group. SLE patients were 
younger and displayed a decreased incidence of respiratory failure compared to patients with other-SRDs. However, the inci-
dences of renal and hematological failure and the presence of shock at admission were higher in the SLE group. The 60-day 
survival rates were similar. 
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Patient outcome assessment
Introduction
Systemic rheumatic diseases (SRDs) are common in the general population (1,2). In addition, they are one of the 
leading causes of death among young and middle-aged women (1). Approximately 10 to 25% of all patients with SRDs 
visiting Emergency Departments require hospital admission, and 30% of these patients are admitted to the intensive 
care unit (ICU) (3). The mortality of critically ill rheumatologic patients is higher than for the general ICU population with 
similar disease severity (2,4-6). 
Multiple organ dysfunction syndrome (MODS) is the most common cause of death in the ICU population (7). The 
severity of MODS measured by the sequential organ failure assessment (SOFA) score, as well as SOFA-derived vari-
ables, are strongly associated with clinical outcomes (8,9). Currently, there are few data regarding MODS evaluation in 
www.bjournal.com.brBraz J Med Biol Res Online Provisional Version
ON
LIN
E 
PR
OV
IS
IO
NA
L
critically ill rheumatologic patients (2). Moreover, the accuracy of other physiologically based severity scores, such as 
the acute physiology and chronic health evaluation II (APACHE II), in predicting clinical outcomes in these patients is 
unclear (5,10,11).
Patients with systemic lupus erythematosus (SLE) usually present polymorphic manifestations. In view of this com-
plexity, we hypothesized that SLE patients might have worse outcomes than other-SRD patients. Therefore, the primary 
aim of this study was to determine whether critically ill patients with SLE have the same incidence and severity of organ 
dysfunction as critically ill patients with other-SRDs and to compare their clinical outcomes. Secondarily, we attempted 
to determine the prognostic factors in a general sample of SRD patients and to report the incidence of organ dysfunc-
tions and outcomes in this population.
Patients and Methods
Study design and sampling
This was a single-center cohort study consisting of 1780 consecutive critical patients admitted to the clinical ICU of 
the Emergency Department, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo (HCFMUSP), 
in Brazil. Data were retrieved from April 2003 to January 2010, and all variables were collected prospectively; however, 
hypotheses were generated before data analysis and after data collection. The present study was approved by the Eth-
ics Committee (CAPPesq) of Hospital das Clínicas, Universidade de São Paulo. Due to its strictly observational design, 
informed consent was waived. 
All patients with the diagnoses of SRD were eligible for inclusion, and only the first ICU admission was considered. 
Only patients with SRDs diagnosed either before or during the ICU stay were retrieved. The SRDs analyzed in the pres-
ent study were as follows: SLE (12), polymyositis/dermatomyositis (13), Wegener’s granulomatosis (14), rheumatoid 
arthritis (15), mixed connective tissue disease (16), spondyloarthritis (17), systemic sclerosis (18), Sjögren syndrome 
(19), primary antiphospholipid syndrome (20), pulmonary-renal syndrome (21), Takayasu’s arteritis (22), Behçet’s disease 
(23), Churg-Strauss syndrome (24), and adult-onset Still’s disease (25). The exclusion criteria were as follows: SRDs 
induced by drugs and paraneoplastic syndromes, and rheumatic diseases that were irrelevant to our purpose, such as 
fibromyalgia, osteoarthritis, rheumatic fever, gout, and undefined SRD. 
We included 116 critically ill patients with SRD from the 1780 admitted patients (7%). Patients were clustered into 
SLE (59 patients) and other-SRD (57 patients) groups.
Data collection
Data were extracted from our database, including demographics (age, gender, ethnicity), co-morbidities (systemic 
arterial hypertension, diabetes mellitus, chronic renal failure, chronic obstructive pulmonary disease, chronic liver disease, 
chronic heart failure, infection, previous thrombotic event), admission diagnosis, source of admission, type of admission, 
use of noninvasive positive pressure ventilation (NPPV), mechanical ventilation (MV), renal replacement therapy (RRT), 
or vasoactive drugs. The follow-up of patients was extended to death or hospital discharge, and the ICU and hospital 
length of stay (LOS) were recorded.
Definitions
Infections. Defined by microbiologically documented processes (bacteriological and opportunistic) or suspicious (e.g., 
suggested by radiographic, clinical and/or laboratory findings). Sepsis syndrome, severe sepsis and septic shock were 
defined according to the Consensus Conference (26).
Activity of rheumatic disease (flare). Acute exacerbation attributable to SRD, after the exclusion of infections, drug 
reactions, metabolic disturbances, and hypervolemia based on laboratory and clinical data.
Infection and flare. Defined when it was not possible to characterize only one of the previous conditions.
Adverse reaction from treatment drugs. Life-threatening severe reactions to drugs used in the treatment of the re-
spective SRD. 
Thrombotic event. Defined as deep vein thrombosis, arterial thrombosis and/or pulmonary embolism. Each of these 
diagnoses required radiographic or pathological documentation.
Bleeding. Gastrointestinal tract or central nervous system bleeding (e.g., intracranial hemorrhage or acute subarach-
noid hemorrhage) as well as alveolar hemorrhage, which was diagnosed according to established criteria (27).
Shock. In this category, we included all patients with cardiovascular dysfunction (systolic blood pressure <90 mmHg 
refractory to 20-30 mL/kg of crystalloid volume infusion or need for vasopressor therapy).
Acute renal failure. Defined as a creatinine increase >0.3 mg/dL between two measurements up to 48 h apart, acute 
RRT requirement at any time (e-1 for 6 consecutive hours. Patients with chronic renal failure were considered in this 
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definition (acute renal failure exacerbating chronic dysfunction) if creatinine was increased 1.5-fold from baseline (28).
Respiratory failure. Patients with an oxygen saturation <90% or PaO2 <60 mmHg at room air, patients with a P/F 
ratio <300 or need for mechanical ventilation due to respiratory causes (excluding neurological events and anesthesia 
for surgery).
Central nervous system disturbances. Patients with stroke, intracranial hemorrhage, meningitis, seizures, or coma.
Organ function and severity scores
Clinical and laboratory data for the APACHE II were reported as the worst value within 24 h after admission (29). A 
daily evaluation of any degree of organ dysfunction according to the SOFA score was performed (30), with the worst 
value for each of the six organ systems (neurological, cardiovascular, respiratory, renal, hepatic, and hematological) 
being collected on admission and every 24 h thereafter. Severe dysfunction was defined as a SOFA score higher than 
2 for the organ in question (30). SOFA-derived variables were calculated as follows: total SOFA was calculated as the 
sum of each organ score daily during the ICU stay for each patient; maximum SOFA was the highest score of total SOFA 
during the ICU stay; mean SOFA was calculated as the arithmetic mean of total SOFA values during the ICU stay; total 
maximum SOFA (TMS) was calculated as the sum of the worst score for each organ independent of the day, and delta 
SOFA was the difference between the maximum SOFA and total SOFA at admission. We also recorded the day of the 
ICU stay during which the maximum SOFA occurred (9,30). 
Statistical analysis
The normality of variables was tested using the Kolmogorov-Smirnov goodness-of-fit model. Data are reported as 
means ± SD or median and 25th and 75th percentiles if they were parametrically or non-parametrically distributed, 
respectively. Baseline characteristics of the SLE and other-SRD groups were compared using the Mann-Whitney or 
the unpaired t-test as appropriate. The Fisher exact test or chi-square statistics (with Yates correction) were used for 
dichotomous variables. The Kaplan-Meier curve was used to evaluate the survival of both groups; the probability of 
survival was compared using the log-rank test. To compare the effect of imbalances (age, gender, chronic renal failure, 
chronic lung disease, admission syndrome, and hemorrhage evidence) between SLE and other-SRD patients, the Cox 
proportional hazard analysis was used. 
To evaluate the prognostic factors for in-hospital mortality among all 116 patients, we performed a binary logistic 
regression. After univariate analysis, variables with P values less than 0.2 were included in multivariate analysis with 
likelihood-ratio backward elimination. The P values used as entry and removal criteria in the backward elimination were 
0.05 and 0.10, respectively. Single colinearity was evaluated with the Pearson’s correlation with the independent variable, 
and multicolinearity was evaluated with the variance inflation factor (VIF). To explore the impact of organ dysfunction 
severity on in-hospital mortality, three models were developed: 1) a model using admission SOFA; 2) a model using 
maximum SOFA, and 3) a model using TMS (to explore the impact of the worst function of each organ on in-hospital 
mortality irrespective of the time of occurrence). Significance was considered as P < 0.05 (two-tailed). All statistical tests 
were performed using the commercial package SPSS 13.0 for Windows (USA).
Results
The general features of all 116 patients (59 SLE and the 57 other-SRD patients) enrolled in the study are shown in 
Table 1. Data regarding only SLE patients such as autoantibodies, immunosuppression and time from SLE diagnosis 
to ICU admission are shown in Table 2. Table 3 indicates whether life support was used on the patients during the ICU 
stay as well as other diagnoses and outcomes. Eleven patients had adverse reactions to treatment drugs: severe acute 
pancreatitis in 4 patients, cumarinic poisoning in 3 patients, toxic epidermal necrolysis in 2 patients, myelosuppression 
in 1 patient, and acute pulmonary edema secondary to intravenous human immunoglobulin in 1 patient.
The 60-day probability of survival is shown in Figure 1. Panel A shows the probability of crude survival of SLE vs 
other-SRD patients, and Panel B shows the probability of survival of SLE vs other-SRD patients adjusted for age, gen-
der, chronic renal failure, chronic obstructive pulmonary disease, admission syndrome, and any hemorrhage evidence. 
The characterization of organ dysfunctions observed at admission and during the ICU stay, using the SOFA score, is 
shown in Table 4. 
The univariate and multivariate analyses of data associated with the in-hospital mortality of the whole group of criti-
cally ill rheumatologic patients are shown in Table 5. To explore the impact of the occurrence of non-synchronic organ 
dysfunction on in-hospital mortality, we constructed a third model using TMS instead of the maximum SOFA as an 
independent variable to measure organ dysfunction. In this new multivariate model, age [odds ratio (OR) = 1.05, 95% 
confidence interval (CI) = 1.02-1.09, P = 0.004, VIF = 1.060)], total maximum SOFA (OR = 1.32, 95%CI = 1.19-1.47, P 
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< 0.001, VIF = 1.056) and admission from the emergency unit (OR = 0.19, 95%CI 0.05-0.64, P = 0.007, VIF = 1.011) 
were independently associated with in-hospital mortality.
Discussion
Few studies have analyzed the clinical features, prognosis and outcome of critically ill SRD patients in the ICU (2,4-6). 
In the present study, we report one of the largest samples in the current literature analyzing these patients. Moreover, 
to our knowledge, this is the first study comparing SLE and other-SRD patients and also analyzing the SOFA score for 
the diagnosis and quantification of organ dysfunction in this setting.
The ICU and in-hospital mortality rates were similar to the most recent reports (5,11) and lower than in previous stud-
ies (4,6,31) (Table 3). This fact may reflect advances in ICU management and rheumatologic care. Godeau et al. (4,6) 
have shown that the mortality of critically ill SLE patients is lower than that of other-SRD patients. In contrast, Ansell et al. 
(31) have suggested that SLE patients have a particularly poor survival rate. However, these studies were not designed 
to evaluate this issue. The present study demonstrated that the mortality of the SLE group did not differ from that of the 
other-SRD patient group, which does not support the pre-study hypothesis (Figure 1). The crude mortality was lower in 
the SLE group despite several features classically associated with worse outcomes, such as major incidence of chronic 
renal failure (32), higher LOS in the hospital and higher incidence of shock at admission to the ICU (33). However, SLE 
patients were predominantly young women, a factor strongly associated with better outcome (29,34). Ultimately, the 
balance of these characteristics resulted in a similar mortality rate.
The association of alveolar hemorrhage, pneumonia, chronic obstructive pulmonary disease, and SRD with pulmonary 
involvement in the other-SRD group could explain the higher respiratory SOFA at admission. In this group, the occurrence 
of severe respiratory dysfunction (respiratory SOFA >2) was also higher than in the SLE group (Table 4). However, dur-
ing the ICU stay the incidence of severe respiratory dysfunction was similar between groups. Furthermore, the need for 
noninvasive and invasive MV was similar for all groups, which may indicate a higher ICU incidence of adverse events 
in the SLE group. It is interesting to note that our incidence of MV (52%) was lower than reported for other case series 
(68-87%) (10,31). A possible explanation for this fact was the use of NPPV (40% of patients), a factor classically as-
sociated with fewer intubations in patients with hypoxemic respiratory failure (35). SLE patients had more chronic renal 
failure before ICU admission, which could explain the higher renal SOFA score on admission and during the ICU stay. 
Renal failure is common in SLE and strongly related to clinical outcome (3,31). However, in our patients, when taking 
into account only severe renal failure (renal SOFA >2) on ICU admission and during the ICU stay, the occurrence was 
similar for all groups, as was the need for RRT. The development of acute renal failure associated with critical illness in 
other-SRD patients could explain the similar severe renal dysfunction and the need for RRT in both groups. Moreover, 
the frequency of thrombocytopenia has been reported to be as high as 40%, and is strongly associated with mortality in 
SLE (36). In this setting, the marked occurrence of hematological dysfunction in the SLE group during the ICU stay may 
represent not only disease activity but also dysfunction secondary to other critically ill injuries (37).
Analysis of the group as a whole (116 patients) showed that our patients are younger than those in other studies 
on SRDs in the literature (4,6) (Table 1). This may be related to the current recognition of milder forms of SRD and the 
prevalence in the cited studies (4,6) of patients with diagnoses of rheumatoid arthritis and systemic vasculitis, diseases 
typically diagnosed in older patients (1). Respiratory failure was the main cause of ICU admission in our study, a finding 
similar to other samples of SRD (4) and SLE (10) patients. Regarding the etiology of ICU admission syndrome, infec-
tion and flare were common. Moreover, in 22% of our patients the etiologic diagnosis of ICU admission syndrome was 
related to infection plus flare, which highlights the difficulty in distinguishing between the two diagnoses (Table 1). The 
differential diagnosis between infection and flare is a challenge in general SRD patients, mainly because the therapeutic 
approaches are antagonistic. Thus, the treatment instituted often includes empirical antibiotic treatment plus systemic 
immunosuppression (38).
Regarding the prognostic factors (Table 5), the APACHE II score was not independently associated with in-hospital 
mortality, which agrees with previous studies showing that the APACHE II is not associated (10,31) or weakly associ-
ated (5,11) with mortality. Therefore, it seems that the APACHE II score is not a good tool for predicting mortality in SRD 
patients. This is probably related to the small number of SRD patients used in the validation of the score (29) and to the 
fact that SRD patients are generally younger than the general population of critically ill patients. In our study age was 
independently and consistently associated with in-hospital mortality as well as admission from the emergency room. 
This result agrees with the current literature, in which young age and emergency room admission (when compared to 
admission from the ward) are protective factors in general critically ill patients (39). Bleeding was common in our pa-
tients, and it has been related to poor outcomes in critically ill patients with SLE (10). In contrast, we did not find it as an 
outcome factor in multivariate analysis, probably because the incidence of bleeding in the SLE group was lower than in 
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the other-SRD patients. Moreover, alveolar hemorrhage, the most common site of bleeding in our sample, was directly 
associated with the need for MV, which was one of the main factors associated with outcome. We found that the SOFA 
score was a good predictor of in-hospital mortality in SRD patients, as it was in other specific critically ill patients (40). 
However, admission SOFA was not associated with in-hospital mortality in the multivariate analysis, probably because 
severe respiratory dysfunction requiring MV was a stronger mortality predictor in the same analysis. Therefore, a worsen-
ing of other organ functions during ICU stay (maximum SOFA) was independently associated with in-hospital mortality, 
suggesting that the process leading to death is preceded by more severe MODS (7).
This study has several limitations. First, our sample was retrieved from a single tertiary hospital and, thus, our find-
ings may not be applicable to other settings. Second, it is a retrospective analysis, and therefore we did not have access 
to some variables, such as the assessment of SRD activity using specific scores. Third, we did not evaluate long-term 
quality of life in our patients, an important outcome in view of the fact that SRD and critical illness are chronically debili-
tating processes.
In this large cohort of critically ill rheumatologic individuals, SLE and other-SRD patients had similar 60-day mortality. 
SLE patients were younger, had more renal and hematological failure, less respiratory failure and an increased incidence 
of shock at admission. The major dysfunctions in the total sample at admission and during ICU stay were respiratory and 
renal. Older patients and those with a need for MV and an increased number of failed organs were more susceptible to 
poor outcomes. In our sample, APACHE II was not an adequate mortality predictor. However, further prospective studies 
with these patients should be performed.
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Table 1. Characteristics of all patients at admission.
Whole group 
(N = 116)
Other-SRDs 
(N = 57)
SLE 
(N = 59)
Characteristics
Age, years (mean ± SD) 41 ± 17 50 ± 16 32 ± 12* 
Female/male gender, N (%)  97 (84)/19 (16)  16 (72)/41 (28) 56 (95)/3 (5)**
Race (black/white), N (%)  19 (25)/87 (75)  10 (18)/47 (82)  19 (32)/40 (68)
APACHE II score (mean ± SD) 18.62 ± 7.98 18.81 ± 7.38 18.43 ± 8.58
Medical/surgical patients, N (%) 101 (87)/15 (13) 48 (84)/9 (16) 53 (90)/6 (10)
Origin of patients, N (%)
Ward 70 (60) 36 (64) 34 (58)
Emergency room 37 (32) 17 (30) 20 (34)
Other ICU 5 (4) 2 (4) 3 (5)
Operating room 4 (3) 2 (4) 2 (3)
Rheumatologic diagnosis, N (%)
SLE 59 (51) - 59 (100)
Wegener’s granulomatosis 10 (9) 10 (18) -
Dermatomyositis/polymyositis 10 (9) 10 (18) -
Rheumatoid arthritis 7 (6) 7 (12) -
Mixed connective tissue
disease
7 (6) 7 (12) -
Spondyloarthritis 5 (4) 5 (9) -
Systemic sclerosis 3 (3) 3 (5) -
Sjögren syndrome 3 (3) 3 (5) -
Antiphospholipid syndrome 3 (3) 3 (5) -
Pulmonary-renal syndrome 3 (3) 3 (5) -
Takayasu’s arteritis 2 (2) 2 (4) -
Behçet’s disease 2 (2) 2 (4) -
Churg-Strauss syndrome 1(1) 1(2) -
Adult-onset Still’s disease 1(1) 1(2) -
Co-morbid conditions, N (%)
Systemic arterial hypertension 54 (47) 29 (51) 25 (42)
Diabetes mellitus 7 (6) 3 (5) 4 (7)
Chronic renal failure 29 (25) 9 (16) 20 (34)**
Chronic heart failure 17 (15) 7 (12) 10 (17)
Chronic obstructive
pulmonary disease
5 (4) 5 (9) 0 (0)**
Previous thrombotic event 26 (22) 13 (23) 13 (22)
Syndrome at admission, N (%)
Respiratory failure 53 (46) 35 (61) 18 (31)**
Shock 31 (27) 8 (14) 23 (39)**
CNS disturbances 15 (13) 4 (7) 11 (19)
Renal failure 10 (9) 5 (9) 5 (9)
Postoperative status 7 (6) 5 (9) 2 (3)
Etiology of admission syndrome, N (%)
Infection 42 (36) 23 (40) 19 (32)
Flare 36 (31) 19 (33) 17 (29)
Infection + flare 25 (22) 8 (14) 17 (29)
Other 13 (11) 7 (12) 6 (10)
Other-SRDs = other systemic rheumatic diseases; SLE = systemic lupus erythemato-
sus; APACHE = acute physiological and chronic health evaluation score; CNS = cen-
tral nervous system. *P < 0.05 compared to other-SRDs (unpaired t-test). **P < 0.05 
compared to other-SRDs (Fisher exact test or chi-square statistics, as appropriate).
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Table 2. Characteristics of patients with systemic lupus erythematosus. 
N (%)
Autoantibodiesa
Antinuclear antibodies   55 (100)
Anti-double-stranded DNA (anti-dsDNA) 30 (55)
Anti-RNP 23 (42)
Anti-Sm 14 (25)
Anti-ribosomal P 13 (24)
Anti-Ro/SS-A 21 (38)
Anti-La/SS-B 2 (4)
Anti-cardiolipin  6 (11)
Time from SLE diagnosis to ICU admission - days, median [IQR] 1308 [30-3763]
 Pre-ICU admission During ICU stayb
Immunosuppressive drugs
Chloroquine 23 (39) 1 (2)
Corticosteroids 51 (86) 53 (96)
Mycophenolate mophetil   7 (12) 1 (2)
Tacrolimus 1 (2) 0 (0)
Methotrexate 4 (7) 0 (0)
Cyclophosphamide 10 (17)  7 (13)
Azatioprine 14 (24) 0 (0)
Plasmapheresis 0 (0) 4 (7)
Gammaglobulin 0 (0)   6 (11)
aData not available for 4 patients. bData not available for 5 patients. IQR = interquartile range.
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Table 3. Patient support in the ICU, secondary diagnosis and outcomes.
Whole group (N = 116) Other-SRDs (N = 57) SLE (N = 59)
Support during ICU stay
Non-invasive positive ventilation, N (%) 46 (40) 23 (40) 23 (39)
Mechanical ventilation, N (%) 60 (52) 32 (56) 28 (48)
Length of mechanical ventilation, median [IQR] 2.5 [1-5] 3.5 [1.3-6.8] 2 [1-4]
Renal replacement therapy, N (%) 26 (22) 10 (18) 16 (27)
Use of antibiotics, N (%) 81 (70) 37 (65) 44 (75)
Vasoactive drugs, N (%) 46 (40) 26 (46) 20 (34)
Septic syndrome, N (%) 67 (58) 31 (54) 36 (61)
Sepsis 14 (21) 5 (16) 9 (25)
Severe sepsis 31 (46) 13 (42) 18 (50)
Septic shock 22 (33) 13 (42) 9 (25)
Infection source, N (%)
Lung 32 (48) 21 (68) 11 (31)*
Urinary tract 10 (15) 4 (13) 6 (17)
Skin/soft tissues 8 (12) 4 (13) 4 (11)
Abdominal 8 (12) 1 (3) 7 (19)
Blood infection 6 (9) 1 (3) 5 (17)
CNS 2 (3) 0 (0) 2 (6)
Articular 1 (2) 0 (0) 1 (3)
Evidence of hemorrhage, N (%) 33 (28) 20 (35) 13 (22)
Alveolar 21 (64) 15 (75) 6 (46)*
Abdominal 6 (18) 2 (10) 4 (31)
CNS 6 (18) 3 (15) 3 (23)
Evidence of activity of rheumatic disease, N (%) 61 (53) 27 (47) 34 (58)
New-onset rheumatic disease in the ICU, N (%) 6 (5) 2 (4) 4 (7)
Adverse reaction to drugs/treatment, N (%) 11 (9) 2 (4) 9 (15)
Outcomes
LOS in ICU, median [IQR] 6 [3-8] 5 [2-7] 6 [3-11]
LOS in hospital, median [IQR] 15 [11-30] 12 [8-19] 22 [14-35]**
ICU mortality, N (%) 31 (27) 19 (33) 12 (20)
In-hospital mortality, N (%) 42 (36) 24 (42) 18 (31)
Unit after ICU discharge, N (%)
Ward 61 (72) 27 (71) 34 (72)
Step-down unit 23 (27) 11 (29) 12 (26)
Other ICU 1 (1) 0 (0) 1 (2)
ICU re-admission, N (%) 18 (21) 7 (18) 11 (23)
One 11 (61) 4 (11) 7 (15)
Two or more 7 (39) 3 (8) 4 (9)
Other-SRDs = other systemic rheumatic diseases; SLE = systemic lupus erythematosus; CNS = central nervous 
system; LOS = length-of-stay. IQR = interquartile range. *P < 0.05 compared to other-SRDs (Fisher exact test or 
chi-square statistics as appropriate). **P < 0.05 compared to other-SRDs (Mann-Whitney test).
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Table 4. Characterization of organ dysfunctions using the SOFA score at admission and during the ICU stay.
Whole group (N = 116) Other-SRDs (N = 57) SLE (N = 59)
Admission SOFA, mean ± SD 5.5 ± 4.7 5.1 ± 4.1 5.9 ± 5.1
Neurological 0.8 ± 1.3 0.6 ± 1.1 0.9 ± 1.4
Cardiovascular 0.9 ± 1.4 0.9 ± 1.4 0.8 ± 1.4
Respiratory 1.5 ± 1.3 1.8 ± 1.4 1.2 ± 1.2*
Renal 1.3 ± 1.6 0.9 ± 1.4 1.6 ± 1.6*
Hepatic 0.3 ± 0.7 0.2 ± 0.6 0.4 ± 0.7
Hematological 0.8 ± 1.3 0.6 ± 1.2 1.0 ± 1.3*
Maximum SOFA, mean ± SD 7.4 ± 5.4 6.9 ± 5.3 7.8 ± 5.5
Neurological 1.4 ± 1.6 1.2 ± 1.5 1.5 ± 1.7
Cardiovascular 1.5 ± 1.7 1.5 ± 1.7 1.4 ± 1.6
Respiratory 2.0 ± 1.3 2.2 ± 1.5 1.8 ± 1.3
Renal 1.7 ± 1.7 1.4 ± 1.6 2.0 ± 1.7*
Hepatic 0.4 ± 0.7 0.3 ± 0.6 0.5 ± 0.8
Hematological 1.1 ± 1.4 0.8 ± 1.3 1.4 ± 1.5*
Total maximum SOFA, mean ± SD 8.0 ± 5.8 7.5 ± 5.6 8.6 ± 6.0
Mean SOFA, mean ± SD 5.3 ± 4.5 5.0 ± 4.3 5.6 ± 4.7
Delta SOFA, mean ± SD 1.9 ± 3.3 1.8 ± 3.6 1.9 ± 3.0
Day of maximum SOFA, median [IQR] 1 [1-3] 1 [1-3] 2 [1-3]
No. of dysfunctions at admission, median [IQR] 1 [0-2] 1 [0-2] 1 [0-2]
Occurrence of dysfunction at admission, N (%)
Neurological 19 (16) 7 (12) 12 (20)
Cardiovascular 21 (18) 12 (21) 9 (15)
Respiratory 32 (28) 22 (39) 10 (17)**
Renal 28 (24) 10 (18) 18 (31)
Hepatic 1 (1) 0 (0) 1 (2)
Hematological 15 (13) 5 (9) 10 (17)
No. of dysfunctions during ICU stay, median [IQR] 1 [0-3] 1 [0-2] 1 [0.5-2.5]
Occurrence of dysfunctions during ICU stay, N (%)
Neurological 34 (29) 14 (25) 20 (34)
Cardiovascular 37 (32) 20 (35) 17 (29)
Respiratory 50 (43) 27 (47) 23 (39)
Renal 42 (36) 16 (28) 26 (44)
Renal (attributable to disease activity) 19 (16) 4 (07) 15 (25)**
Hepatic 1 (1) 0 (0) 1 (2)
Hematological 25 (22) 8 (14) 17 (29)**
SOFA = sequential organ failure assessment score; Other-SRDs = other systemic rheumatic diseases; SLE = systemic lupus 
erythematosus; IQR = interquartile range. Organ dysfunction means SOFA >2. *P < 0.05 compared to other-SRDs (unpaired 
t-test). **P ≤ 0.05 compared to other-SRDs (Fisher exact test or chi-square statistics as appropriate). 
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Table 5. Univariate and multivariate analysis of variables associated with the in-hospital mortality of critically ill rheumatologic 
patients.
Variable Univariate analysisa Multivariate analysisb Multivariate analysisc
OR (95%CI) P OR (95%CI) P VIF OR (95%CI) P VIF
Age 1.05 (1.02-1.07) 0.001 1.05 (1.02-1.11) 0.002 1.053 1.05 (1.02-1.09) 0.005 1.060
APACHE II 1.07 (1.02-1.13) 0.008 - - - - - -
Admission SOFA 1.20 (1.09-1.31) <0.001 - - - Not included - -
Maximum SOFA 1.38 (1.23-1.55) <0.001 Not included - - 1.39 (1.22-1.59) <0.001 1.011
No. of co-morbidities 1.48 (1.04-2.09) 0.028 - - - - - -
SLE 0.60 (0.28-1.30) 0.195 - - - - - -
Surgical patients 0.40 (0.11-1.50) 0.173 - - - - - -
Emergency room
admission
0.51 (0.22-1.20) 0.125 0.243 (0.08-0.75) 0.014 1.016 0.18 (0.05-0.63) 0.007 1.056
Infection 1.31 (0.60-2.83) 0.496 - - - - - -
Disease activity 0.63 (0.29-1.35) 0.234 - - - - - -
Bleeding 2.47 (1.08-5.64) 0.033 - - - - - -
Need for MV 9.80 (3.81-25.18) <0.001 6.94 (2.43-19.84) <0.001 1.126 - - -
Need for RRT 3.18 (1.30-7.82) 0.012 - - - - - -
Vasopressor 2.29 (1.05-4.98) 0.036 - - - - - -
aOnly variables with a P value <0.2 in the univariate analysis were used in the multivariate analysis; bMultivariate analysis including 
admission SOFA and not including maximum SOFA; cMultivariate analysis including maximum SOFA and not including admission 
SOFA; OR = odds ratio; CI = confidence interval; VIF = variance inflation factor; APACHE = acute physiological and chronic health 
evaluation score; SOFA = sequential organ failure assessment score; SLE = systemic lupus erythematosus; MV = mechanical ven-
tilation; RRT = renal replacement therapy.
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Figure 1. Actuarial 60-day survival among 116 rheumatologic patients with systemic lupus erythematosus (SLE) or other systemic 
rheumatologic diseases (SRD) after ICU admission. Panel A shows the Kaplan-Meyer probability of crude survival curve, and Panel 
B shows the 60-day probability of the survival curve adjusted for age, gender, chronic renal failure, chronic lung disease, admission 
syndrome, and hemorrhage evidence. aP value using the log-rank test. bP value using the Cox proportional-hazards regression model 
with the non-balanced variables between groups as covariates.
